Todd, Jamie L. https://orcid.org/0000-0003-4247-3693
Neely, Megan L. https://orcid.org/0000-0002-0101-1081
Hellkamp, Anne S.
Culver, Daniel A.
Oldham, Justin M.
Li, Peide
Patel, Divya C.
Palmer, Scott M. https://orcid.org/0000-0002-1370-3771
,
Funding for this research was provided by:
The IPF-PRO/ILD-PRO Registry is supported by Boehringer Ingelheim Pharmaceuticals, Inc and run in collaboration with the Duke Clinical Research Institute and enrolling centers.
Article History
Received: 20 May 2025
Accepted: 19 August 2025
First Online: 27 August 2025
Declarations
:
: The authors have reported to Lung the following conflicts of interest: JLT, MLN, and SMP are faculty members of the Duke Clinical Research Institute, which receives funding support from Boehringer Ingelheim Pharmaceuticals, Inc to run the IPF-PRO/ILD-PRO Registry. JLT also reports grants from AstraZeneca and CareDx and participation in advisory boards for Altavant, Avalyn, Natera, Sanofi, Theravance. SMP also reports research funding paid to his institution from Bristol Myers Squibb and Genentech and has participated on advisory boards for Altavant and Bristol Myers Squibb. ASH is formerly an employee of and now a contractor to the Duke Clinical Research Institute. DAC was formerly a principal investigator at a site in the IPF-PRO/ILD-PRO Registry and has received consulting fees from Boehringer Ingelheim. JMO is a principal investigator at a site in the IPF-PRO/ILD-PRO Registry and has received consulting fees from Boehringer Ingelheim. PL and DCP are employees of Boehringer Ingelheim Pharmaceuticals, Inc.
: All patients provided informed consent.
: Not applicable.
: The IPF-PRO Registry was approved by the Duke University Institutional Review Board (Pro00046131). The IPF-PRO Registry protocol was also approved by the relevant Institutional Review Boards and/or local Independent Ethics Committees prior to patient enrolment at each site.